BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 103 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $77,000 | +196.2% | 16,130 | +23.8% | 0.12% | -74.8% |
| Q1 2020 | $26,000 | -91.4% | 13,030 | -87.6% | 0.46% | +2940.0% |
| Q3 2019 | $301,000 | -32.4% | 104,930 | -10.7% | 0.02% | -40.0% |
| Q2 2019 | $445,000 | -34.3% | 117,530 | +41.2% | 0.02% | -39.0% |
| Q1 2019 | $677,000 | +746.2% | 83,230 | +405.9% | 0.04% | +925.0% |
| Q4 2017 | $80,000 | -94.0% | 16,452 | -93.6% | 0.00% | -94.1% |
| Q3 2017 | $1,339,000 | -21.7% | 255,666 | -16.9% | 0.07% | -25.3% |
| Q2 2017 | $1,710,000 | +1800.0% | 307,616 | +2051.2% | 0.09% | +1720.0% |
| Q4 2016 | $90,000 | -92.4% | 14,300 | -96.6% | 0.01% | -90.6% |
| Q1 2016 | $1,183,000 | +45.9% | 418,308 | +432.1% | 0.05% | +39.5% |
| Q4 2015 | $811,000 | +10.2% | 78,620 | +21.7% | 0.04% | +40.7% |
| Q3 2015 | $736,000 | -66.3% | 64,625 | -73.3% | 0.03% | -64.0% |
| Q1 2015 | $2,186,000 | +56.0% | 242,149 | +69.0% | 0.08% | +15.4% |
| Q3 2014 | $1,401,000 | +1.9% | 143,281 | +32.8% | 0.06% | -9.7% |
| Q2 2014 | $1,375,000 | +29.7% | 107,864 | +7.6% | 0.07% | +28.6% |
| Q1 2014 | $1,060,000 | – | 100,239 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |